The Veri-T Study will test an oral investigational drug called Verdiperstat (BHV-3241) for the treatment of individuals with Semantic Variant Primary Progressive Aphasia (svPPA). Participation will include cognitive, clinical, safety, fluid biomarker, and imaging assessments for up to 6 months.
General Inclusion Criteria:
Age 18-85 (inclusive)
Diagnosed with Semantic Variant Primary Progressive Aphasia (svPPA)
Must have a study partner that is willing to participate as a source of information and who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, or caregiver).
General Exclusion Criteria:
Diagnosis of probable Alzheimer's Disease or any FTLD-associated clinical syndrome other than svPPA will exclude you from being eligible for the Veri-T Study.